SCHEMBL9894499

SCHEMBL9894499

CC(C)(C)OC(=O)N1CCC(c2nc(C3CCOCC3)cn2CCOC2CCCCO2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 1/20 0.39
RPS6KB1 P23443 1/20 0.39
AKT1 P31749 1/20 0.39
RPS6KA1 Q15418 1/20 0.39
RECQL P46063 1/20 0.39
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
TRPV3 Q8NET8 1/20 0.37
HPGD P15428 2/20 0.36
THRB P10828 4/20 0.36
GPR119 Q8TDV5 3/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16457583 0.95 KDM4E (0.39) RPS6KB1AKT1RECQLKDM4EALDH1A1
SCHEMBL9927820 0.95 GPR119 (0.40) RECQLKDM4EALDH1A1MEN1KMT2A
SCHEMBL1662709 0.89 RPS6KB1 (0.38) PRKCBRPS6KB1AKT1RPS6KA1ALDH1A1
SCHEMBL9894518 0.86 GPR119 (0.38) RECQLKDM4EALDH1A1MEN1KMT2A
SCHEMBL2063669 0.86 THRB (0.38) RECQLKDM4EALDH1A1MEN1KMT2A
SCHEMBL1664740 0.86 RECQL (0.43) PRKCBRPS6KB1AKT1RPS6KA1RECQL
SCHEMBL16457523 0.86 GPR119 (0.38) RECQLKDM4EALDH1A1MEN1KMT2A
SCHEMBL1662665 0.85 RPS6KB1 (0.52) PRKCBRPS6KB1AKT1RPS6KA1RECQL
SCHEMBL16457270 0.85 THRB (0.37) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL16457318 0.85 HDAC4 (0.38) PRKCBRPS6KB1AKT1RPS6KA1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491032-B1 AKT INHIBITORS LILLY CO ELI (US) 2014-04-16 EP disclosed
EP-2491032-B1 AKT INHIBITORS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8436002-B2 AKT inhibitors ELI LILLY AND COMPANY (US) 2013-05-07 US disclosed
US-8436002-B2 AKT inhibitors ELI LILLY AND COMPANY (US) 2013-05-07 US disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149684-A1 AKT INHIBITORS AKT2, PIK3CA, AKT3 PRKCB 176/4885RPS6KB1 41/4885AKT1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.